MBX Biosciences earns Buy rating at three investment firms

Mitrade
coverImg
Source: Unsplash

Investing.com -- Three major investment firms started research coverage of MBX Biosciences stock on Tuesday, each assigning a Buy rating to the biotechnology company.


Analysts at Jefferies highlighted the potential of MBX's lead program, MBX-2109, which is currently in Phase II trials for hypoparathyroidism.


They expressed confidence in the company's scientific platform, particularly in the field of endocrine peptides, noting the possibility of significant improvements in treatment duration and the development of better medicines in established commercial areas.


MBX Biosciences's platform is rooted in the extensive peptide and chemistry research of co-founder Dr. Richard DiMarchi, who brings over 20 years of academic experience and a track record of developing approved therapies. The firm underscored the strength of this scientific foundation, which has been augmented by years of R&D at Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO).


“The lead Phase II program in PTH has shown promising Phase I data with favorable pharmacokinetic (PK),” Jefferies analysts said.


“In 4 doses from 200-900ug MBX-2109 showed dose proportional increase in mean concentration and a 7-9-day half-life, supporting weekly dosing vs competitors that are all daily, with < 2-3 days half-life.”


Looking forward, Jefferies anticipates that MBX stock may benefit from upcoming industry catalysts. These include a strong commercial launch expected from competitor ASND in the first quarter of 2025, which could expand the market for hypoparathyroidism treatments.


Moreover, Phase III data from AstraZeneca PLC (LON:AZN) ADR (NASDAQ:AZN) expected in the first half of 2025 could further validate the platform and potentially increase confidence in MBX's improved weekly dosing regimen.


Separately, Stifel and Guggenheim also started coverage on MBX with a Buy rating and optimistic price targets of $40 and $44, respectively.


Stifel's endorsement is based on the strength of MBX's precision endocrin peptides (PEPs) platform, which is engineered to improve pharmaceutical properties, including reducing injection frequency.


The firm anticipates multiple value-driving catalysts within the next 12 months that could demonstrate the platform's capabilities.


Meanwhile, Guggenheim's analysis points to MBX 2109, a once-weekly peptide targeting a market opportunity that the firm estimates to be over $7 billion.


The anticipation of positive Phase 2 results by the third quarter of 2025 is expected to significantly increase the company's share value.


Furthermore, Guggenheim notes MBX 1416, a once-weekly GLP-1 antagonist, as a potential platform-confirming treatment with expected Phase 1 results in the fourth quarter of 2024. The company “is also in the early stages of developing monthly incretin coagonists for obesity,” analysts highlighted.

Read more

  • Gold Price Forecast: Gold Holds Key $3,850 Support, US October Retail Sales May Drive Rebound Toward $4,000
  • Bitcoin Plunges 13% in a Week as Market Retreats to $60,000 Level
  • Nvidia Q3 Earnings Loom as Market Expects Revenue Near $109 Billion: Can NVDA Stock Hold $150?
  • * The content presented above, whether from a third party or not, is considered as general advice only.  This article should not be construed as containing investment advice, investment recommendations, an offer of or solicitation for any transactions in financial instruments.

    goTop
    quote
    Related Articles
    placeholder
    Nvidia posts record $115.8B Q3 revenue, but crypto stays mutedThe crypto market remained subdued on Tuesday despite Nvidia's (NVDA) Q3 earnings release beating analysts' expectations as demand for artificial intelligence infrastructure continued to drive growth across its business.
    Author  FXStreet
    12 hours ago
    The crypto market remained subdued on Tuesday despite Nvidia's (NVDA) Q3 earnings release beating analysts' expectations as demand for artificial intelligence infrastructure continued to drive growth across its business.
    placeholder
    Nvidia Q3 Earnings Loom as Market Expects Revenue Near $109 Billion: Can NVDA Stock Hold $150? As of the close on November 16 ET, Nvidia (NVDA) shares fell 4.12% to close at $156.14, with an intraday low of $155.01 and trading volume of about 334 million shares. Compared with its p
    Author  TradingKey
    Yesterday 09: 10
    As of the close on November 16 ET, Nvidia (NVDA) shares fell 4.12% to close at $156.14, with an intraday low of $155.01 and trading volume of about 334 million shares. Compared with its p
    placeholder
    Weekly Report: The index rose 2.5% while Nvidia fell 12.7% — two equity divergences, one should closeThe S&P 500 rose 2.51% to 7,561.67 and the QQQ rose 3.63% to 679.89 last week, while Nvidia fell 12.75% to 162.85 — a sixth straight weekly loss and 32% below its October record. In the same five sessions, energy equities rose 5.42% while WTI fell 2.52%. Both pairs normally move together (60-day correlations of +0.64 and +0.58). This report ranks which divergence closes first, with the trigger for each.
    Author  Irene Q.
    Nov 16, Mon
    The S&P 500 rose 2.51% to 7,561.67 and the QQQ rose 3.63% to 679.89 last week, while Nvidia fell 12.75% to 162.85 — a sixth straight weekly loss and 32% below its October record. In the same five sessions, energy equities rose 5.42% while WTI fell 2.52%. Both pairs normally move together (60-day correlations of +0.64 and +0.58). This report ranks which divergence closes first, with the trigger for each.
    placeholder
    Anthropic is six times oversubscribed at $1.4 trillion while Nvidia is down 32% — the AI trade has two pricesAnthropic lists on Nasdaq as ANT on Thursday at $70 ~ $78 a share, raising up to $64.4 billion at a target valuation near $1.4 trillion, and the book is reportedly six times covered. In the same six weeks, Nvidia has fallen 32% and the QQQ is 10.9% below its October peak. Private capital and public markets are marking the same AI complex at two very different prices. This piece separates the two books: what the S-1 shows, who is anchoring the $26 billion private placement, and what Thursday's debut would have to do to change the public tape.
    Author  Irene Q.
    Nov 16, Mon
    Anthropic lists on Nasdaq as ANT on Thursday at $70 ~ $78 a share, raising up to $64.4 billion at a target valuation near $1.4 trillion, and the book is reportedly six times covered. In the same six weeks, Nvidia has fallen 32% and the QQQ is 10.9% below its October peak. Private capital and public markets are marking the same AI complex at two very different prices. This piece separates the two books: what the S-1 shows, who is anchoring the $26 billion private placement, and what Thursday's debut would have to do to change the public tape.
    placeholder
    Nvidia reports tomorrow with an interim CEO — $108 billion is the easy numberNvidia closed at 162.85 on Friday, down 12.75% on the week and 32% below its 6 October record, with market value down to $3.92 trillion. The Q3 bar is $108 billion ±2%, and consensus already sits at $108.7 ~ 108.8 billion, so the revenue line is not where the surprise lives. The number that decides the reaction is the 71 ~ 72% Q4 gross-margin trough, followed by a Q4 guide against a $124.9 billion consensus. This piece prices the print, marks the 158.39 line and lays out the three scenarios in a table.
    Author  Irene Q.
    Nov 16, Mon
    Nvidia closed at 162.85 on Friday, down 12.75% on the week and 32% below its 6 October record, with market value down to $3.92 trillion. The Q3 bar is $108 billion ±2%, and consensus already sits at $108.7 ~ 108.8 billion, so the revenue line is not where the surprise lives. The number that decides the reaction is the 71 ~ 72% Q4 gross-margin trough, followed by a Q4 guide against a $124.9 billion consensus. This piece prices the print, marks the 158.39 line and lays out the three scenarios in a table.
    Live Quotes
    Name / SymbolChart% Change / Price
    US500
    US500
    0.00%0.00
    LLY
    LLY
    0.00%0.00

    US Stocks Related Articles

    • 10 Best Day Trading Platforms for Beginners and Active Traders in 2026: A Practical Guide
    • How To Invest in SpaceX Stock in 2026? Everything Investors Need to Know
    • Practice Trading Us Stocks? These Are 10 Best Stock Trading Demo Apps For Beginners
    • ​5 Best Paper Trading Platforms for 2026 (Free Demo Accounts for Beginners & Traders)
    • Wall Street’s Top 10 US Stocks for 2026 vs What Reddit Is Actually Buying
    • Is Mitrade Right for You? A Complete Guide on How to Start Trading CFDs in 5 Steps

    Click to view more